S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
S&P 500   3,956.19 (+0.57%)
DOW   33,788.52 (+0.57%)
QQQ   283.23 (+0.96%)
AAPL   142.61 (+1.18%)
MSFT   246.85 (+1.01%)
META   115.12 (+1.04%)
GOOGL   93.63 (-1.38%)
AMZN   89.78 (+1.49%)
TSLA   171.19 (-1.64%)
NVDA   167.77 (+4.08%)
NIO   13.21 (+5.01%)
BABA   92.99 (+5.28%)
AMD   70.45 (+0.44%)
T   19.25 (-0.26%)
MU   55.37 (+2.88%)
CGC   3.16 (-2.47%)
F   13.18 (+0.61%)
GE   84.42 (-0.68%)
DIS   92.51 (+0.39%)
AMC   6.22 (+2.81%)
PYPL   75.29 (+1.17%)
PFE   50.79 (+1.09%)
NFLX   308.59 (+0.06%)
NASDAQ:LPTX

Leap Therapeutics - LPTX Stock Forecast, Price & News

$0.49
+0.01 (+2.96%)
(As of 12/8/2022 10:45 AM ET)
Add
Compare
Today's Range
$0.49
$0.50
50-Day Range
$0.48
$0.92
52-Week Range
$0.45
$3.45
Volume
3,563 shs
Average Volume
495,699 shs
Market Capitalization
$48.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
629.2% Upside
$3.50 Price Target
Short Interest
Healthy
2.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

537th out of 1,027 stocks

Pharmaceutical Preparations Industry

242nd out of 503 stocks

LPTX stock logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

LPTX Leap Therapeutics, Inc.
Leap Therapeutics: Q4 Earnings Insights
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings
11/12/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/10/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+608.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-40,590,000.00
Pretax Margin
-14,214.93%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$1.22 per share

Miscellaneous

Free Float
86,643,000
Market Cap
$48.94 million
Optionable
Not Optionable
Beta
0.51

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 53)
    CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director
    Comp: $1.04M
  • Mr. Augustine J. Lawlor (Age 65)
    Chief Operating Officer
    Comp: $693.83k
  • Dr. Cynthia A. Sirard (Age 52)
    Chief Medical Officer
    Comp: $691.22k
  • Mr. Mark O'Mahony (Age 51)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 54)
    VP and Head of Regulatory Affairs & Quality
  • Dr. Jason S. Baum Ph.D.
    VP & Head of Translational Medicine
  • Dr. Walter Newman (Age 76)
    Sr. Research Fellow













LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2023?

1 Wall Street analysts have issued 12-month price targets for Leap Therapeutics' stock. Their LPTX share price forecasts range from $2.50 to $4.00. On average, they anticipate the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 629.2% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2022?

Leap Therapeutics' stock was trading at $3.24 at the start of the year. Since then, LPTX stock has decreased by 85.2% and is now trading at $0.48.
View the best growth stocks for 2022 here
.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,380,000 shares, a decline of 32.6% from the October 31st total of 3,530,000 shares. Based on an average daily volume of 680,600 shares, the short-interest ratio is presently 3.5 days.
View Leap Therapeutics' Short Interest
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The business earned $0.38 million during the quarter, compared to analysts' expectations of $0.38 million.

What other stocks do shareholders of Leap Therapeutics own?
What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (7.55%), 683 Capital Management LLC (2.29%), BlackRock Inc. (1.19%), Key Client Fiduciary Advisors LLC (1.13%), Tri Locum Partners LP (0.72%) and Marshall Wace LLP (0.63%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $0.48.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $47.53 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 12/8/2022 by MarketBeat.com Staff